Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: results from an international survey and discussion programme.

[1]  J. Macdonald,et al.  Methotrexate for maintenance of remission in Crohn's disease. , 2014, The Cochrane database of systematic reviews.

[2]  G. Kaplan,et al.  Budesonide for maintenance of remission in Crohn's disease. , 2014, The Cochrane database of systematic reviews.

[3]  B. Feagan,et al.  Methotrexate for induction of remission in refractory Crohn's disease. , 2014, The Cochrane database of systematic reviews.

[4]  E. Purssell.  Feverish illness in children Assessment and initial management in children younger than 5 years , 2013 .

[5]  J. Macdonald,et al.  Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. , 2013, The Cochrane database of systematic reviews.

[6]  B. Feagan,et al.  Methotrexate for induction of remission in refractory Crohn's disease. , 2012, The Cochrane database of systematic reviews.

[7]  S. Schreiber.  Certolizumab pegol for the treatment of Crohn’s disease , 2011, Therapeutic advances in gastroenterology.

[8]  R. Gearry,et al.  Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease , 2011, Inflammatory bowel diseases.

[9]  J. Gisbert,et al.  Early Use of Azathioprine Has a Steroid Sparing Effect on Recently Diagnosed Crohn's Disease Patients , 2011 .

[10]  S. Fine.  Adalimumab for the treatment of fistulas in patients with Crohn's disease. , 2011, Inflammatory bowel diseases.

[11]  C. Glasmacher,et al.  Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. , 2011, Gastroenterology.

[12]  U. Kopylov,et al.  The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab , 2011, Alimentary pharmacology & therapeutics.

[13]  J. West,et al.  Risk of Cancer in Inflammatory Bowel Disease Treated With Azathioprine: A UK Population-Based Case–Control Study , 2010, The American Journal of Gastroenterology.

[14]  F. Carrat,et al.  Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy , 2010, Gut.

[15]  W. Petritsch,et al.  Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial , 2010, Gut.

[16]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[17]  C. Porter,et al.  Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[18]  H. Tilg,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. , 2010, Journal of Crohn's & colitis.

[19]  C. O'Morain,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. , 2010, Journal of Crohn's & colitis.

[20]  P. Rutgeerts,et al.  Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. , 2010, Gastroenterology.

[21]  P. Skolnik,et al.  A Practical Guide to Vaccinating the Inflammatory Bowel Disease Patient , 2010, The American Journal of Gastroenterology.

[22]  P. Rutgeerts,et al.  The efficacy and safety of a third anti‐TNF monoclonal antibody in Crohn’s disease after failure of two other anti‐TNF antibodies , 2010, Alimentary pharmacology & therapeutics.

[23]  Laurent Beaugerie,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. , 2006, Journal of Crohn's & colitis.

[24]  M. Picco,et al.  Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease , 2010 .

[25]  P. Rutgeerts,et al.  Immunosuppression-associated lymphoma in IBD , 2009, The Lancet.

[26]  F. Carrat,et al.  Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study , 2009, The Lancet.

[27]  P. Rutgeerts,et al.  Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. , 2009, Gastroenterology.

[28]  G. Kaplan,et al.  Systematic review: the short‐term and long‐term efficacy of adalimumab following discontinuation of infliximab , 2009, Alimentary pharmacology & therapeutics.

[29]  A. Cheifetz,et al.  Interventions for prevention of post-operative recurrence of Crohn's disease. , 2009, The Cochrane database of systematic reviews.

[30]  P. Rutgeerts,et al.  Mucosal healing predicts long‐term outcome of maintenance therapy with infliximab in Crohn's disease , 2009, Inflammatory bowel diseases.

[31]  B. Sands,et al.  Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[32]  P. Rutgeerts,et al.  Corticosteroids but not infliximab increase short‐term postoperative infectious complications in patients with ulcerative colitis , 2009, Inflammatory bowel diseases.

[33]  M. Vos,et al.  961 Infliximab Discontinuation in Crohn's Disease Patients in Stable Remission On Combined Therapy with Immunosuppressors: A Prospective Ongoing Cohort Study , 2009 .

[34]  Steven J Brown,et al.  W1114 Methotrexate in Thiopurine Refractory Crohn's Disease - a Retrospective Cohort Study , 2009 .

[35]  P. Rutgeerts,et al.  Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease: Results From the CHARM Trial , 2009, The American Journal of Gastroenterology.

[36]  A. Eriksson,et al.  Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease , 2009, Alimentary pharmacology & therapeutics.

[37]  E. Benchimol,et al.  Budesonide for maintenance of remission in Crohn's disease. , 2009, The Cochrane database of systematic reviews.

[38]  S. Hanauer,et al.  Management of Crohn's Disease in Adults , 2001, The American Journal of Gastroenterology.

[39]  M. Picco.  Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study , 2009 .

[40]  M. Cepoiu,et al.  Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. , 2009, The Cochrane database of systematic reviews.

[41]  J. Macdonald,et al.  Methotrexate for maintenance of remission in Crohn's disease. , 2009, The Cochrane database of systematic reviews.

[42]  J. Mary,et al.  Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[43]  H. Tilg,et al.  European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.

[44]  K. Van Steen,et al.  Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort , 2008, Gut.

[45]  P. Rutgeerts,et al.  Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. , 2008, Gastroenterology.

[46]  S. Saxena,et al.  Preoperative Steroid Use and Risk of Postoperative Complications in Patients With Inflammatory Bowel Disease Undergoing Abdominal Surgery , 2008, The American Journal of Gastroenterology.

[47]  R. D'Incà,et al.  Can Calprotectin Predict Relapse Risk in Inflammatory Bowel Disease? , 2008, The American Journal of Gastroenterology.

[48]  R. Panaccione,et al.  Hepatosplenic T cell lymphoma in inflammatory bowel disease , 2008, Gut.

[49]  A. Cohen,et al.  A Randomized Trial of Methotrexate in Combination With Infliximab for the Treatment of Crohn's Disease , 2008 .

[50]  A. Staiano,et al.  Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[51]  Jeffrey R Curtis,et al.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[52]  P. Rutgeerts,et al.  Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. , 2008, Gastroenterology.

[53]  L. Peyrin-Biroulet,et al.  Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[54]  A. Griffiths,et al.  Traditional corticosteroids for induction of remission in Crohn's disease. , 2008, The Cochrane database of systematic reviews.

[55]  W. Sandborn,et al.  T1133 Efficacy and Tolerability of Certolizumab Pegol Are Sustained Over 18 Months: Data from PRECISE 2 and Its Extension Studies (PRECISE 3 and 4) , 2008 .

[56]  P. Rutgeerts,et al.  946 Corticosteroids Pose An Increased Risk for Serious Infection: An Interim Safety Analysis of the ENCORE Registry , 2008 .

[57]  S. McCartney,et al.  W1235 Efficacy of Methotrexate in Crohns Disease Patients Previously On Thiopurine Therapy , 2008 .

[58]  G. D'Haens,et al.  920 Adalimumab Maintains Long-Term Remission in Moderately to Severely Active Crohn's Disease After Infliximab Failure: 1-Year Follow-Up of Gain Trial , 2008 .

[59]  A. Zinsmeister,et al.  Risk factors for opportunistic infections in patients with inflammatory bowel disease. , 2008, Gastroenterology.

[60]  W. S. Haubrich.  Paneth of Paneth Cells , 2008 .

[61]  M. Vos,et al.  Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial , 2008, The Lancet.

[62]  M. Färkkilä,et al.  Crohn's disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn's disease activity index and endoscopic findings , 2008, Inflammatory bowel diseases.

[63]  A. Michalsen,et al.  Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices , 2008, The American Journal of Gastroenterology.

[64]  Y. Yazdanpanah,et al.  Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis , 2007, Gut.

[65]  G. D'Haens,et al.  Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial , 2008 .

[66]  A. Griffiths,et al.  Budesonide for induction of remission in Crohn's disease. , 2008, The Cochrane database of systematic reviews.

[67]  A. Ford,et al.  Mycophenolate mofetil therapy for refractory inflammatory bowel disease , 2007, Inflammatory bowel diseases.

[68]  S. Targan,et al.  Differences in the management of Crohn’s disease among experts and community providers, based on a national survey of sample case vignettes , 2007, Alimentary pharmacology & therapeutics.

[69]  A. Griffiths,et al.  Hepatosplenic T‐cell lymphoma in adolescents and young adults with Crohn's disease: A cautionary tale? , 2007, Inflammatory bowel diseases.

[70]  M. Vatn,et al.  Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. , 2007, Gastroenterology.

[71]  P. Rutgeerts,et al.  American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. , 2007, Gastroenterology.

[72]  J. Mate,et al.  Thiopurine-Induced Liver Injury in Patients With Inflammatory Bowel Disease: A Systematic Review , 2007, The American Journal of Gastroenterology.

[73]  M. De Vos,et al.  Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine , 2007, Gut.

[74]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.

[75]  M. Silverberg,et al.  Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[76]  R. Modigliani,et al.  A simple biological score for predicting low risk of short‐term relapse in Crohn's disease , 2006, Inflammatory bowel diseases.

[77]  S. Dorn.  Predictors of Crohn's disease. , 2006, Gastroenterology.

[78]  W. Sandborn,et al.  Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[79]  W. Tremaine,et al.  American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. , 2006, Gastroenterology.

[80]  Province,et al.  Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). , 1989, Gut.

[81]  A. Zinsmeister,et al.  Correlation of C‐Reactive Protein With Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease , 2005, Inflammatory bowel diseases.

[82]  C. Brensinger,et al.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine , 2005, Gut.

[83]  R. Modigliani,et al.  A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. , 2005, Gastroenterology.

[84]  W. Leslie,et al.  Therapy Insight: osteoporosis in inflammatory bowel disease—advances and retreats , 2005, Nature Clinical Practice Gastroenterology &Hepatology.

[85]  R. Caprilli,et al.  Small Intestine Contrast Ultrasonography: An Alternative to Radiology in the Assessment of Small Bowel Disease , 2005, Inflammatory bowel diseases.

[86]  B. Feagan,et al.  Methotrexate for induction of remission in refractory Crohn's disease. , 2005, The Cochrane database of systematic reviews.

[87]  P. Rutgeerts,et al.  Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. , 2004, Gastrointestinal endoscopy.

[88]  A. Taschieri,et al.  Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. , 2004, Gastroenterology.

[89]  R. Thisted,et al.  Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. , 2004, Gastroenterology.

[90]  M. Dubinsky.  Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[91]  D. Sanders,et al.  Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease , 2004, Gut.

[92]  P. Rutgeerts,et al.  Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.

[93]  A. Griffiths,et al.  Corticosteroids for maintenance of remission in Crohn's disease. , 2003, The Cochrane database of systematic reviews.

[94]  S. Targan,et al.  6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. , 2003, Gastroenterology.

[95]  W. Leslie,et al.  AGA technical review on osteoporosis in gastrointestinal diseases. , 2003, Gastroenterology.

[96]  J. Escher,et al.  Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease , 2003, Alimentary pharmacology & therapeutics.

[97]  E. Louis,et al.  Safe treatment of thiopurine S-methyltransferase deficient Crohn’s disease patients with azathioprine , 2003, Gut.

[98]  J. Belaiche,et al.  A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism , 2002 .

[99]  F. Carbonnel,et al.  Long-Term Evolution of Disease Behavior of Crohn's Disease , 2002, Inflammatory bowel diseases.

[100]  J. Belaiche,et al.  Inflammatory Bowel Disease A Positive Response to Infliximab in Crohn Disease: Association with a Higher Systemic Inflammation Before Treatment But Not With -308 TNF Gene Polymorphism , 2002, Scandinavian journal of gastroenterology.

[101]  W. Sandborn.  Rational dosing of azathioprine and 6-mercaptopurine , 2001, Gut.

[102]  J. Markowitz,et al.  A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. , 2000, Gastroenterology.

[103]  B. Bonaz,et al.  Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. , 2000, Gastroenterology.

[104]  O Bernell,et al.  Risk factors for surgery and postoperative recurrence in Crohn's disease. , 2000, Annals of surgery.

[105]  P. Rutgeerts,et al.  Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. , 1999, Gastrointestinal endoscopy.

[106]  S. Targan,et al.  Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. , 1999, Gastroenterology.

[107]  B. Feagan.  Methotrexate treatment for Crohn's disease. , 1998, Inflammatory bowel diseases.

[108]  P. Rutgeerts,et al.  Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. , 1997, Gastroenterology.

[109]  M. Gerig,et al.  A controlled double blind study of azathioprine in the management of Crohn's disease. , 1995, Gut.

[110]  Loyd,et al.  Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. , 1995, The New England journal of medicine.

[111]  D. Thompson,et al.  Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. , 1995, Alimentary pharmacology & therapeutics.

[112]  G. Greenberg,et al.  Oral Budesonide for Active Crohn's Disease , 1994 .

[113]  G. Greenberg,et al.  Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. , 1994, The New England journal of medicine.

[114]  R. Modigliani,et al.  Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. , 1992, Gastroenterology.

[115]  T. Bayless,et al.  Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. , 1991, Gastroenterology.

[116]  P. Rutgeerts,et al.  Predictability of the postoperative course of Crohn's disease. , 1990, Gastroenterology.

[117]  R. Modigliani,et al.  Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. , 1990, Gastroenterology.

[118]  A. Stuck,et al.  Risk of infectious complications in patients taking glucocorticosteroids. , 1989, Reviews of infectious diseases.

[119]  R. Weinshilboum,et al.  Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism , 1989, Clinical pharmacology and therapeutics.

[120]  J Y Mary,et al.  Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). , 1989, Gut.

[121]  R. Kozarek,et al.  Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. , 1989, Annals of internal medicine.

[122]  K. Ewe,et al.  European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. , 1984, Gastroenterology.

[123]  R. F. Harvey,et al.  A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY , 1980, The Lancet.

[124]  R. Summers,et al.  National Cooperative Crohn's Disease Study: results of drug treatment. , 1979, Gastroenterology.